北京市金杜（深圳）律师事务所 关于中广核核技术发展股份有限公司 2025 年第三次临时股东会 之法律意见书 致：中广核核技术发展股份有限公司 北京市金杜（深圳）律师事务所（以下简称本所）接受中广核核技术发展 股份有限公司（以下简称公司）的委托，根据《中华人民共和国公司法》（以下 简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、中国证券 监督管理委员会颁布的《上市公司股东会规则》（以下简称《股东会规则》）等 中华人民共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中 国香港特别行政区、中国澳门特别行政区和中国台湾省）现行有效的法律、行 政法规、规章和规范性文件和《中广核核技术发展股份有限公司章程》（以下简 称《公司章程》）的规定，指派律师出席了公司于 2025 年 9 月 15 日召开的 2 025 年第三次临时股东会（以下简称本次股东会），并就本次股东会相关事项出 具本法律意见书。 为出具本法律意见书，本所经办律师审查了以下文件，包括但不限于： 1． 经公司 2024 年年度股东会审议通过的《公司章程》； 2． 公司 2025 年 8 月 29 日刊登于巨潮资讯网（网址为 http ...

证券代码：000881 证券简称：中广核技 公告编号：2025-046 中广核核技术发展股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开的日期、时间： （1）现场会议召开日期、时间：2025 年 9 月 15 日（星期一）下午 3:30； （2）网络投票日期、时间：通过深圳证券交易所交易系统进行网络投票的具 体时间为：2025 年 9 月 15 日上午 9:15 至 9:25、9:30 至 11:30、下午 1:00 至 3:00； 通过深圳证券交易所互联网投票系统投票的具体时间为2025 年9 月15日上午 9:15 至下午 3:00 期间的任意时间。 2.会议召开方式：本次股东会采取现场投票与网络投票相结合的方式。 3.现场会议召开地点：深圳市福田区深南大道 2002 号中广核大厦北楼 19 层 881 会议室。 4.召集人：公司董事会。 5.主持人： ...

特此公告。 中广核核技术发展股份有限公司董事会 2025年9月12日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或者重大 遗漏。 中广核核技术发展股份有限公司（以下简称"公司"或"中广核技"）于2025年8月27日召开的第十届董事 会第三十次会议审议通过了《关于审批注销首期第二个行权期及离职人员股票期权的议案》，董事会同 意25名离职人员已获授但尚未行权的股票期权共计168.0005万份予以注销；因2024年度公司未完成业绩 考核目标，对所有首批授予及预留授予共205名激励对象所持有的第二个行权期已获授的股票期权共计 685.6619万份予以注销。详见公司于2025年8月29日在证券时报、中国证券报、上海证券报和巨潮资讯 网（http://www.cninfo.com.cn）披露的《关于股票期权激励计划第二个行权期行权条件未成就及注销部 分股票期权的公告》（公告编号2025-041）。 经中国证券登记结算有限责任公司深圳分公司审核确认，上述合计853.6624万份股票期权已于2025年9 月11日注销完毕。本次注销符合法律、行政法规、部门规章、规范性文件、公司章程、股权 ...

证券日报网讯 9月11日晚间，中广核技发布公告称，经中国证券登记结算有限责任公司深圳分公司审核 确认，853.6624万份股票期权已于2025年9月11日注销完毕。 （文章来源：证券日报） ...

特此公告。 中广核核技术发展股份有限公司 关于部分股票期权注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 中广核核技术发展股份有限公司（以下简称"公司"或"中广核技"）于 2025 年 8 月 27 日召开的第十届董事会第三十次会议审议通过了《关于审批注销首期 第二个行权期及离职人员股票期权的议案》，董事会同意 25 名离职人员已获授但 尚未行权的股票期权共计 168.0005 万份予以注销；因 2024 年度公司未完成业绩 考核目标，对所有首批授予及预留授予共 205 名激励对象所持有的第二个行权期 已获授的股票期权共计 685.6619 万份予以注销。详见公司于 2025 年 8 月 29 日 在证券时报、中国证券报、上海证券报和巨潮资讯网（http://www.cninfo.com.cn） 披露的《关于股票期权激励计划第二个行权期行权条件未成就及注销部分股票期 权的公告》（公告编号 2025-041）。 经中国证券登记结算有限责任公司深圳分公司审核确认，上述合计 853.6624 万份股票期权已于 2025 年 9 月 11 日注销完毕 ...

Core Viewpoint - The performance briefing held by China General Nuclear Power Corporation (CGN) highlighted the progress of various projects, including the Huaxi proton medical project and the development of new products, while addressing investor concerns about the company's future growth and profitability [1] Group 1: Project Updates - The Huaxi proton medical project has completed equipment production but is not expected to finish acceptance testing within the year due to site readiness issues [1] - Proton therapy order business is facing delays as most public hospitals have not yet entered the procurement phase due to funding and construction challenges [1] - The company is actively tracking demand and communicating with potential hospitals to secure orders [1] Group 2: Product Development - The subsidiary Juner is developing a special PEEK product for applications in electronics, aerospace, and machinery, but it has not yet generated revenue [1] - The high-performance silicon photomultiplier packaging production line is expected to reach mass production conditions in the first half of 2025, with ongoing market development and initial sales orders [1] Group 3: Financial and Strategic Outlook - Revenue from the nuclear power sector accounts for less than 10% of the company's total revenue [1] - The company aims to achieve profitability in 2025 through cost reduction, product transformation, innovation enhancement, and deepening reforms [1] - There are currently no risks of delisting or other risk warnings for the company [1] Group 4: Corporate Governance and Future Plans - The company has no plans for a private placement at this time but will disclose any future plans as required [1] - Emphasis is placed on market expansion through product-centric strategies and active engagement with stakeholders [1] - The company is committed to embracing artificial intelligence to enhance productivity and drive business development [1]

Group 1: Project Status and Orders - The Huaxi Proton Medical Project's equipment has completed factory production, but installation cannot begin until site conditions are met, making year-end acceptance unlikely [2] - The company has not received new orders for proton therapy equipment in the last two years due to long preparation times for funding and construction, despite some hospitals obtaining configuration permits [2] - The company has completed technical breakthroughs and design for a miniaturized proton therapy system [2] Group 2: Product Development and Revenue - The isotope main equipment arrived at the production base in June 2025, with production planned for 2026 [3] - The company’s subsidiary is developing a special plastic product (Peek) for various industries, but it has not yet generated revenue [3] - The company’s revenue from the nuclear power sector is less than 10% [3] Group 3: Financial Performance and Strategies - The company aims to achieve profitability by reducing costs, enhancing strategic customer collaboration, and upgrading products based on market needs [3] - The company has faced significant losses for several years but is not currently at risk of being delisted according to stock exchange rules [4] - The company is focused on improving operational performance and enhancing investor relations to align intrinsic value with market value [4] Group 4: Corporate Governance and Future Plans - The company is not considering a private placement to increase shareholding ratios at this time [4] - The company is committed to completing its asset disposal work by the end of 2025 [4] - The company is actively embracing artificial intelligence to drive high-end, green, and intelligent transformation [5]

Core Insights - The company, CGN Technology (中广核技), reported a net profit decline of 15.29% year-on-year for the first half of 2025, with total revenue decreasing by 8.29% to 2.593 billion yuan [1] - The second quarter showed a slight revenue increase of 0.94% year-on-year, but the net profit for this quarter fell significantly by 62.48% [1] Financial Performance - Total revenue for 2025 was 2.593 billion yuan, down from 2.828 billion yuan in 2024, reflecting an 8.29% decrease [1] - The net profit attributable to shareholders was -99.8153 million yuan, compared to -86.5778 million yuan in the previous year, marking a 15.29% decline [1] - Gross margin improved to 13.4%, up 6.86% year-on-year, while net margin decreased to -3.86%, down 32.87% [1] - Total expenses (selling, administrative, and financial) amounted to 382 million yuan, accounting for 14.73% of revenue, an increase of 3.66% year-on-year [1] Cash Flow and Debt Analysis - Cash flow per share was -0.06 yuan, a significant decline of 148.21% year-on-year, indicating cash flow challenges [1] - The company’s cash and cash equivalents increased by 35.53% to 1.48 billion yuan, while interest-bearing liabilities rose by 6.40% to 3.32 billion yuan [1] - The cash flow situation is concerning, with cash to current liabilities ratio at 55.56% and the average operating cash flow to current liabilities ratio at 17.41% over the past three years [4] Investment Returns - The company's historical return on invested capital (ROIC) has been weak, with a median of 5.13% over the past decade and a particularly poor ROIC of -6.93% in 2023 [3] - The company has reported losses in two of its 26 annual reports since going public, indicating a fragile business model [3]

Core Points - The company announced that the conditions for the second exercise period of the stock option incentive plan were not met, leading to the cancellation of certain stock options [1][5][4] - A total of 685.6619 thousand stock options held by 205 incentive objects will be canceled due to the failure to meet performance assessment targets for 2024 [5][4] - The stock options granted to 25 departing employees, totaling 168.0005 thousand, will also be canceled as they no longer qualify as incentive objects [4][3] Summary of Related Sections Stock Option Incentive Plan Approval Process - The stock option incentive plan was approved by the board and relevant authorities, with the first grant date set for December 30, 2022, awarding 26.48 million stock options at an exercise price of 7.33 yuan per share [2][1] - The plan included a public solicitation for proxy voting rights from shareholders [2] Stock Option Grant Details - On April 25, 2023, an additional 950 thousand stock options were granted to 4 qualifying incentive objects at an exercise price of 8.11 yuan per share [3][2] - The total number of stock options granted in the first phase was 25.96 million to 257 individuals, including directors and key personnel [2][1] Cancellation of Stock Options - The company will cancel stock options for departing employees and those who did not meet the exercise conditions, totaling 291 thousand options for 25 individuals [3][4] - The cancellation of stock options is in accordance with the company's incentive plan management regulations and does not require further shareholder approval [5][4] Impact of Cancellation - The cancellation of stock options is not expected to have a significant impact on the company's financial status or operations, and the incentive plan will continue to be implemented [5][4] - Legal opinions confirm that the cancellation has received necessary approvals and complies with relevant regulations [5][4]

Core Insights - Company reported a total operating revenue of 2.593 billion yuan, ranking 27th among disclosed peers, a decrease of 234 million yuan or 8.29% year-on-year [1] - The net profit attributable to shareholders was -99.8153 million yuan, ranking 165th among peers, a decline of 13.2375 million yuan compared to the same period last year [1] - The net cash inflow from operating activities was -55.117 million yuan, ranking 153rd among peers, a decrease of 169 million yuan or 148.21% year-on-year [1] Financial Ratios - The latest debt-to-asset ratio was 48.99%, ranking 123rd among peers, an increase of 1.06 percentage points from the previous quarter and 2.15 percentage points from the same period last year [1] - The latest gross profit margin was 13.40%, ranking 131st among peers, an increase of 1.04 percentage points from the previous quarter and 0.86 percentage points year-on-year [1] - The latest return on equity (ROE) was -1.94%, ranking 156th among peers, a decrease of 0.37 percentage points from the same period last year [1] Earnings Per Share - The diluted earnings per share was -0.11 yuan, ranking 157th among peers, a decrease of 0.01 yuan compared to the same period last year [1] Asset Management Efficiency - The latest total asset turnover ratio was 0.24 times, ranking 85th among peers, a decrease of 0.01 times or 3.69% year-on-year [2] - The latest inventory turnover ratio was 2.01 times, ranking 104th among peers, a decrease of 0.28 times or 12.40% year-on-year [2]